← Back to Search

Stem Cell Therapy

hMSC for Coronavirus

Phase 2
Recruiting
Led By Santosh Kesari, MD
Research Sponsored by Stemedica Cell Technologies, Inc.
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 9 months
Awards & highlights

Study Summary

This trial is testing if an experimental antibody drug can improve lung function in patients with moderate to severe lung injury from COVID-19 or other potential viral and bacterial pathogens.

Eligible Conditions
  • Coronavirus

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~9 months
This trial's timeline: 3 weeks for screening, Varies for treatment, and 9 months for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Survival
Secondary outcome measures
Number of patients with treatment-related adverse events as assessed by CTCAE v4.0

Trial Design

2Treatment groups
Experimental Treatment
Placebo Group
Group I: hMSCsExperimental Treatment1 Intervention
hMSCs will be given via IV administration.
Group II: Lactated Ringer's SolutionPlacebo Group1 Intervention
Lactated Ringer's Solution will be given via IV administration.

Find a Location

Who is running the clinical trial?

Stemedica Cell Technologies, Inc.Lead Sponsor
5 Previous Clinical Trials
130 Total Patients Enrolled
bioRASI, LLCIndustry Sponsor
13 Previous Clinical Trials
3,362 Total Patients Enrolled
Lev Verkh, PhD/MSStudy DirectorStemedica Cell Technologies, Inc.
~10 spots leftby May 2025
Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top